Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia
Anemia is a common and important complication in patients with chronic kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis stimulating agents (ESAs) and iron. Hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors (HIF-PHIs) have been developed to t...
Saved in:
Main Authors: | Xue Wang (Author), Cuiting Wei (Author), Delong Zhao (Author), Xuefeng Sun (Author), Fengge Zhu (Author), Yan Mei (Author), Qian Ma (Author), Guangyan Cai (Author), Xiangmei Chen (Author), Ping Li (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
by: Dinghua Chen, et al.
Published: (2023) -
Effectiveness of iron supplementation in reducing iron deficiency anemia in India
by: Aakriti Gupta, et al.
Published: (2017) -
Directly observed iron supplementation for control of iron deficiency anemia
by: Mohan Bairwa, et al.
Published: (2017) -
Infantile Hemangioma Treated with Propranolol Readmission Trends, Complications of Therapy, and Cost: A PHIS Database Study
by: Muhammad Abu-Rmaileh, et al.
Published: (2022) -
Role of Vitamin K in CKD: Is Its Supplementation Advisable in CKD Patients?
by: Patrycja Grzejszczak, et al.
Published: (2021)